A confirmation of ASXL1 as biological marker of normal cytogenetic acute myeloid leukemia with myelodysplasia-related changes (AML-MRC): A case successfully treated with CPX-351

Capelli, Debora; Diego, Menotti

doi:10.52768/2766-7820/1966

The platform will undergo maintenance on Sep 14 at about 7:45 AM EST and will be unavailable for approximately 2 hours.

J Clin Images Med Case Rep

2022

DOI: 10.52768/2766-7820/1966

|View full text |Cite

A confirmation of ASXL1 as biological marker of normal cytogenetic acute myeloid leukemia with myelodysplasia-related changes (AML-MRC): A case successfully treated with CPX-351

Debora Capelli¹,

Menotti Diego²

Abstract: We here report the case of a 56 yr old patient affected by acute myeloid leukemia with myelodisplasia related changes (AML‐MRC), ASXL1, successfully transplanted after CPX-351 treatment. Prats Martin et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Publication Types

Select...

Relationship

Self Cite0

Independent0

Authors

Journals

Cited by 0 publications

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

No citations

Set email alert for when this publication receives citations?

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

A confirmation of ASXL1 as biological marker of normal cytogenetic acute myeloid leukemia with myelodysplasia-related changes (AML-MRC): A case successfully treated with CPX-351

Abstract: We here report the case of a 56 yr old patient affected by acute myeloid leukemia with myelodisplasia related changes (AML‐MRC), ASXL1, successfully transplanted after CPX-351 treatment. Prats Martin et al.

Cited by 0 publications

References 14 publications

No citations

Contact Info

Product

Resources

About